BTOG 2021 | COVID-19 and the future of lung cancer treatment in the UK
Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, talks about the impacts of the COVID-19 pandemic on the treatment of lung cancer, highlighting the importance of recovering diagnostic and treatment services, and the future role of screening and neoadjuvant and adjuvant immunotherapy. Dr Newsom-Davis also discusses the use of KRAS inhibitors, such as sotorasib, and antibody-drug conjugates. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.
Disclosures
Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, has received support to attend educational conferences from AstraZeneca, BMS, Boehringer Ingelheim, Lilly, MSD, Otsuka, Roche and Takeda; has participated in an advisory role for Amgen, Bayer, AstraZeneca, BMS, Boehringer Ingelheim, Eli-Lilly, Janssen, MSD, Novartis, Otsuka, Pfizer, Roche, Sanofi and Takeda; and has participated in speaker’s bureaus for AstraZeneca, MSD, Roche and Takeda; and has participated in an independent data monitoring committee for Blueprint.
